Dual Antiplatelet Therapy for Acute Stroke and TIA: Current Best Practice and Emerging Strategies
Published: 09 November 2020
28m 37sPart 6 Q&A and Summary
This educational symposium was first broadcast in the joint European Stroke Organisation and World Stroke Organization (ESO-WSO 2020) Virtual Conference held 7-9 November.
The programme focuses upon emerging data and best practice in the use of antiplatelet therapy for the treatment of Acute Stroke and TIA
- To Highlight the Continued High Unmet Need for Strategies to Prevent Stroke or Death for Patients Experiencing Acute Stroke or TIA
- To Outline the Guidelines on the Use of Dual Antiplatelet Therapy for Patients Presenting with Acute Stroke or TIA
- To Examine Recent Evidence from Clinical Trials on Novel Strategies for Improving Outcomes for Patients Presenting with Acute Stroke or TIA and How These Data and Insights Can Be Applied in Clinical Practice
More from this programme
Chairperson’s Welcome and Introduction
Secondary Prevention after Acute Minor Stroke or TIA: Understanding the Ongoing Risk
Current Best Practice: Evidence-Based Antiplatelet Therapy for Secondary Stroke Prevention
Evolving Role of Dual Antiplatelet Therapy for Stroke Prevention: Advancing Best Practice for Patients at High Risk
Clinical Decision Making for the Patient Presenting with Acute Stroke
Pierre Amarenco is Professor of Neurology at Paris University, France. He also serves as Chair of the Department of Neurology and Stroke Center, and also of the SOS-TIA Clinic at Bichat University Hospital in Paris. He has published more than 450 original contributions, research papers, and reviews.